Interrogate the impact of IKZF1 deletion on therapy-outcomes of adults with common B-cell acute lymphoblastic leukemia. One hundred sixty-five consecutive adults with common B-cell ALL were tested for IKZF1 deletion and for BCR/ABL. Deletions in IKZF1 were detected using multiplex RQ-PCR, multiplex fluorescent PCR, sequence analysis and multiplex ligation-dependent probe amplification (MLPA). BCR/ABL was detected using RQ-PCR. All subjects received chemotherapy and some also received an allotransplant and tyrosine kinase-inhibitors. Multivariate analyses were done to identify associations between IKZF1 deletion and other variables on non-relapse mortality (NRM), cumulative incidence of relapse (CIR), leukemia-free survival (LFS) and survival. Amongst subjects achieving complete remission those with IKZF1 deletion had similar 5-year non-relapse mortality (NRM) (11 % [2–20 %] vs. 16 % [4–28 %]; P = 0.736), a higher 5-year cumulative incidence of relapse (CIR) (55 % [35–76 %] vs. 25 % [12–38 %]; P = 0.004), and worse 5-year leukemia-free survival (LFS) (33 % [16–52 %] vs. 59 % [42–73 %]; P = 0.012) and survival (48 % [33–62 %] vs. 75 % [57–86 %]; P = 0.002). In multivariate analyses IKZF1 deletion was associated with an increased relapse (relative risk [RR] =2.7, [1.4–5.2]; P = 0.002), a higher risk of treatment-failure (inverse of LFS; RR = 2.1, [1.2–3.6]; P = 0.007) and a higher risk of death (RR = 2.8, [1.5–5.5]; P = 0.002). The adverse impact of IKZF1 deletion on outcomes was stronger in subjects without vs. with BCR-ABL1 and in subjects receiving chemotherapy-only vs. an allotransplant. IKZF1 deletion was independently-associated with a higher relapse risk and worse LFS and survival in adults with common B-cell ALL after adjusting for other prognostic variables and differences in therapies. These data suggest IKZF1 deletion may be a useful prognostic variable in adults with common B-cell ALL, especially in persons without BCR-ABL1 and those receiving chemotherapy-only. Transplants appear to overcome the adverse impact of IKZF1 deletion on therapy-outcomes but confirmation in a randomized study is needed. The trial was registered in 2007 with the Beijing Municipal Government (Beijing Municipal Health Bureau Registration N: 2007–1007).

This study aimed to analyze the effects of the initial MLL-partial tandem duplication (PTD) expression levels on clinical outcomes in 36 MLL-PTD-positive acute myeloid leukemia (AML) patients between 2014 and 2016. ROC curves showed 1.0% MLL-PTD as the optimal diagnostic cutoff for complete remission (CR). Nineteen and 17 cases had MLL-PTD <1.0% (low-level group) and ≥1.0% (high-level group), respectively. The FAB type distribution (M2 incidence, 100% vs. 53%, p = .003) and double-CEBPA-mutation incidence (37% vs. 0%, p = .008) significantly differed between the groups, as did the CR rates after the first (78.9% vs. 35.3%, p = .008) and second chemotherapies (84.2% vs. 47.1%, p = .001). High MLL-PTD level was the only independent factor affecting the CR rate (odds ratio = 0.16, p = .024). The 24-month overall survival was significantly lower in the high-level group (52.6% vs. 29.4%, p = .043). In conclusion, AML patients with high initial MLL-PTD levels have lower induction CR and survival rates.